Gene Variant Heart Failure Risk Cut by Diabetes Drug

A study analyzing data from the DECLARE-TIMI 58 trial has revealed that the SGLT2 inhibitor dapagliflozin, commonly prescribed for type 2 diabetes, may offer significant protection against heart failure in individuals with genetic variants associated with cardiomyopathy. This progressive heart muscle disease affects a subset of patients with diabetes and an increased risk profile.

The research, involving over 12,000 adults, identified approximately 121 participants who carried inherited gene variants predisposing them to cardiomyopathy. Over a median follow-up of 4.2 years, dapagliflozin demonstrated a notable reduction in heart failure hospitalizations. This protective effect was substantially more pronounced in carriers of the genetic variant, showing an eight-fold stronger reduction compared to non-carriers.

Experts highlight that these findings are particularly encouraging for preventive cardiology. Historically, identifying genetic predispositions to cardiomyopathy offered limited therapeutic options beyond risk assessment. Now, the possibility exists to leverage genetic information for more precise interventions. SGLT2 inhibitors are already recognized for their cardiovascular and kidney benefits across various patient groups.

This research suggests that genetic data could refine treatment strategies, identifying individuals who may benefit exceptionally from early SGLT2 inhibitor therapy, even before symptoms manifest. While further confirmation through additional clinical trials is necessary due to the limited sample size of carriers, this study presents a compelling hypothesis for a more targeted approach to heart failure prevention.